Fatty Acid Elongase (B108)

Women diagnosed with active breast cancer or ovarian cancer have elevated fatty acid elongase activity. Abnormal cell growth (i.e., cancer) results in the activation of certain elongase enzymes which are used to make the long-chain polyunsaturated fatty acids required to populate the sn-2 position of membrane phospholipids. The predominate fatty acid synthetized is arachidonic acid (20:4), which is made from the essential dietary omega-6 fatty acid linoleic acid (18:2). In contrast, the essential dietary omega-9 fatty acid oleic acid (18:1) cannot be used to make these fatty acids. Accordingly, when cell growth is activated, linoleic acid is selectively depleted relative to oleic acid. 

To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar B108, Blood Tests and Biomarkers (Series B).

Women diagnosed with active breast cancer or ovarian cancer have a low 18:2/18:1 ratio, which is indicative of overactive ELOV5 activity. This ratio returns to normal following treatment. 

ProdromeScan measures selected 18:1 and 18:2 containing phospholipid species to determine the relative 18:2/18:1 ratio. 

Dr. Goodenowe explains the relevant research and literature regarding fatty acid elongase metabolism in seminar B108 – Fatty Acid Elongase.